论文部分内容阅读
目的:研究CDl33在卵巢浆液性肿瘤中的表达及临床病理意义。方法:采用免疫组织化学EnvisionTM二步法检测100例浆液性肿瘤组织中CDl33的表达,并分析其与临床病理的关系。结果:CDl33阳性表达率在良性浆液性肿瘤、交界性卵巢浆液性肿瘤及浆液性腺癌分别为0%、26.1%和69.6%,浆液性腺癌的表达高于交界性卵巢浆液性肿瘤及良性浆液性瘤,有显著性差异(P<0.05);CDl33表达与浆液性腺癌不同病理学分级、临床分期具显著相关性(P<0.05);与患者年龄及残留病灶大小无相关性(P>0.05)。结论:CDl33过表达是影响浆液性卵巢肿瘤的生物学行为的重要因素,并对浆液性卵巢肿瘤的病情进展有作用。
Objective: To investigate the expression of CD133 in ovarian serous tumors and its clinicopathological significance. Methods: The expression of CD133 in 100 serous tumors was detected by immunohistochemistry EnvisionTM two-step method and its relationship with clinical pathology was analyzed. Results: The positive rates of CD133 in benign serous tumors, borderline ovarian serous tumors and serous adenocarcinomas were 0%, 26.1% and 69.6%, respectively. The expression of CD133 in serous adenocarcinoma was higher than that in borderline ovarian serous tumors and benign serous (P <0.05). There was a significant correlation between the expression of CD133 and the pathological grades and clinical stages of serous adenocarcinoma (P <0.05), but not with the age and residual tumor size (P> 0.05) . Conclusion: Overexpression of CD133 is an important factor that affects the biological behavior of serous ovarian tumors and plays an important role in the progression of serous ovarian tumors.